Core Viewpoint - Rosen Law Firm is reminding purchasers of KinderCare Learning Companies, Inc. common stock about the upcoming lead plaintiff deadline for a class action lawsuit related to the company's October 2024 IPO [1]. Group 1: Class Action Details - Investors who purchased KinderCare common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by October 14, 2025 [3]. - The lawsuit claims that the registration statement was false and/or misleading, failing to disclose incidents of child abuse and neglect at KinderCare facilities, which exposed the company to material risks [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions for investors [4]. - The firm has been recognized for its performance in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking highly in the industry since 2013 [4].

Core Insights - The SMART Trial presents the two-year results of the largest international head-to-head randomized control trial comparing Evolut and SAPIEN TAVR devices, primarily enrolling women with small aortic annuli [1][3][4] - Evolut TAVR demonstrated superior valve performance and significantly less bioprosthetic valve dysfunction (BVD) compared to SAPIEN TAVR, which is critical for patients with small aortic annuli [2][4][6] Company Overview - Medtronic plc is a global leader in healthcare technology, headquartered in Galway, Ireland, with a mission to alleviate pain, restore health, and extend life [6] - The company employs over 95,000 people across 150 countries, focusing on innovative technologies that address challenging health problems [6][7] Industry Context - Aortic stenosis affects approximately 1.5 million people in the U.S., with a significant portion of the global market having small aortic annuli, necessitating tailored valve selection [5] - The SMART Trial's findings are expected to inform and personalize treatment decisions for patients with symptomatic severe aortic stenosis [2][4]